-
Your Trusted Generics Medicine Supplier
- +91 84484 44095 / 8071 555 357
-
Mumbai, India
Eng
简体中文
العربيّة
Professional Medical Information
Welcome to the Healthcare Professional Resources section for Mefloquine Hydrochloride Tablets USP 250mg. Here you will find comprehensive medical information, clinical data, and professional resources to support your clinical practice and patient care.
Medical Information & Clinical Data
Prescribing Information
Complete prescribing information including dosage, administration, contraindications, and warnings.
View DetailsClinical Pharmacology
Pharmacokinetics, mechanism of action, and clinical pharmacology data for Mefloquine.
View DetailsClinical Studies
Summary of clinical trials, efficacy data, and safety profile from clinical studies.
View StudiesDrug Interactions
Comprehensive information on potential drug interactions and contraindications.
View DetailsSafety Data
Adverse reactions, safety monitoring, and pharmacovigilance information.
View Safety DataPatient Resources
Patient education materials, counseling guides, and adherence support tools.
View ResourcesComplete Prescribing Details
Indications:
- Treatment of mild to moderate acute malaria caused by Plasmodium falciparum or Plasmodium vivax
- Prophylaxis of malaria caused by Plasmodium falciparum, including mefloquine-resistant strains
Dosage:
- Treatment: 5 tablets (1250 mg) as a single dose
- Prophylaxis: 1 tablet (250 mg) once weekly, starting 1 week before travel
Mefloquine is contraindicated in patients with:
- Known hypersensitivity to mefloquine or related compounds (quinine, quinidine)
- History of seizures or epilepsy
- Severe psychiatric disorders including depression, anxiety, or psychosis
- Concurrent use of chloroquine (may increase risk of convulsions)
Neuropsychiatric Effects:
- May cause anxiety, depression, hallucinations, or psychotic reactions
- Monitor patients for psychiatric symptoms during and after treatment
- Discontinue if neuropsychiatric symptoms develop
Cardiac Effects:
- May cause QT interval prolongation
- Use with caution in patients with cardiac arrhythmias
- Avoid concomitant use with other QT-prolonging drugs
Common (≥10%):
- Nausea, vomiting, diarrhea
- Dizziness, vertigo
- Headache
- Sleep disturbances, abnormal dreams
Serious:
- Neuropsychiatric reactions
- Seizures
- Cardiac arrhythmias
- Severe skin reactions
Mechanism of Action & Pharmacokinetics
Mefloquine is a 4-quinoline methanol compound with antimalarial activity. It acts against the erythrocytic forms of Plasmodium falciparum and Plasmodium vivax.
Mechanism of Action
Inhibits heme polymerization in the malaria parasite, leading to toxic heme accumulation and parasite death.
Pharmacokinetics
Peak plasma concentrations reached 6-8 hours after oral administration; half-life of 2-3 weeks.
Distribution
Extensively bound to plasma proteins (99%); distributes into erythrocytes and tissues.
Important Interaction Information
Contraindicated
- Chloroquine
- Quinidine
- Quinine
Use with Caution
- Anti-arrhythmics
- Antipsychotics
- Antidepressants
- Other QT-prolonging drugs
Patient Education Materials
